Breaking the Taboo Associated with Hemorrhoidal Disease
- Details
- Category: Bayer
Experts assume that more than 50 percent of Americans over the age of 50 have had symptoms related to hemorrhoidal disease at some point in their lives(1).
Nycomed well positioned in emerging markets
- Details
- Category: Nycomed
Nycomed's 2010 performance continued to show above industry average growth in emerging markets, as well as strong growth of Key Products (excluding pantoprazole), Regional and Local prescription (Rx) drugs.
Roche Annual General Meeting: dividend raised by 10%
- Details
- Category: Roche
Roche's Annual General Meeting, which was held in Basel, has approved all of the Board of Directors' proposals. The 818 shareholders in attendance, representing 142,963,212 or 89.4% of a total of 160,000,000 bearer shares, approved the 2010 Annual Report and financial statements.
Nycomed's novel COPD therapy roflumilast receives FDA approval
- Details
- Category: Nycomed
Nycomed's US partner Forest Laboratories, Inc. (NYSE: FRX) announced that DalirespTM (roflumilast) was approved by the US Food and Drug Administration (FDA) as a treatment to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations
Genzyme Recognizes International Rare Disease Day by Launching New Patient Advocacy Grant Program
- Details
- Category: Genzyme
Genzyme Corporation (NASDAQ: GENZ) recognized International Rare Disease Day with the launch of a new program, the Genzyme Patient Advocacy Leadership Awards (PAL Awards).
Results Published in The Lancet Demonstrate Superiority of XGEVA(TM) (Denosumab)
- Details
- Category: Amgen
Amgen (Nasdaq: AMGN) announced the publication of results from a Phase 3 head-to-head trial that compared XGEVA(TM) (denosumab) to Zometa(R) (zoledronic acid) in preventing bone complications called skeletal-related events (SREs) in 1,901 men with prostate cancer and bone metastases.
Bayer and Onyx Initiate Phase III Trial of Nexavar® in Combination with Chemotherapy
- Details
- Category: Bayer
Bayer HealthCare and Onyx Pharmaceuticals, Inc. announced that the companies have begun enrolling patients in a Phase III randomized, double-blind, placebo-controlled trial evaluating Nexavar® (sorafenib) tablets in combination with the oral chemotherapeutic agent, capecitabine, versus placebo plus capecitabine for the treatment of patients with advanced breast cancer.
More Pharma News ...
- Lundbeck delivers at the top-end of guidance and momentum is expected to continue in 2011
- Sanofi Pasteur and International Vaccine Institute Partner against Dengue
- ONGLYZA™ US label update regarding use in renally impaired adults with type 2 diabetes
- Forest Laboratories to Acquire Clinical Data, Inc.
- Novartis gains positive CHMP opinion for Rasilamlo(TM)
- Sanofi-aventis to Acquire Genzyme for $74.00 in Cash per Share Plus Contingent Value Right
- Genzyme Reports Financial Results for Fourth Quarter of 2010 and Full Year